Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy-Reference-Cited by-同舟云学术

Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy

Published:2011-07-12 Issue:11 Volume:52 Page:2069-2075
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Motomura Kazuya,Natsume Atsushi,Fujii Masazumi,Ito Motokazu,Momota Hiroyuki,Wakabayashi Toshihiko

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.596967

Reference39 articles.

1. Primary intracerebral malignant lymphoma: report of 248 cases

2. Primary central nervous system lymphoma: a retrospective study

3. Primary central nervous system lymphoma in Japan 1995?1999: changes from the preceding 10�years

4. Primary Central Nervous System Lymphoma in an Asian Population: A 15-Year Experience

5. Trends in survival from primary central nervous system lymphoma, 1975-1999

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma;Cancer Medicine;2022-12-07

2. Modern aspects of the diagnosis and treatment of primary central nervous system lymphomas;Onkologiya. Zhurnal imeni P.A.Gertsena;2022

3. A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial;Blood Advances;2021-10-20

4. Treatment of primary central nervous system lymphomas;Oncohematology;2021-06-07

5. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy;Japanese Journal of Clinical Oncology;2020-05-29